This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Reply to More on Placebo Response

Dan J. Stein, MD, PhD; David S. Baldwin, MD; Ornah T. Dolberg, MD; Nicolas Despiegel, MSc; and Borwin Bandelow, MD

Published: December 14, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We are pleased that our article1 on the placebo response in the escitalopram randomized controlled trials has generated some discussion.

Dr. Mattes’s first point is that there are fewer untreated depressed patients in the community than there used to be. Epidemiologic data certainly indicate that over the past decade or more, there has been an increase in treatment rate in patients with a mental disorder in the United States.2‘ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 68

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...